|
시장보고서
상품코드
1766574
졸레드론산 시장 : 적응증별, 투여 경로별, 용량별, 연령층별, 성별, 제품 유형별, 최종사용자별, 지역별Zoledronic Acid Market, By Indication, By Route of Administration, By Dosage Strength, By Age Group, By Gender, By Product Type, By End User, By Geography |
||||||
졸레드론산 시장은 2025년에 53억 8,000만 달러로 추정되며, 2032년에는 76억 2,000만 달러에 달할 것으로 예측되며, 2025년부터 2032년까지 연평균 성장률(CAGR) 5.1%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 53억 8,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR | 5.10% | 2032년 가치 예측 | 76억 2,000만 달러 |
졸레드론산 세계 시장은 제약 산업에서 중요한 부문으로, 주로 뼈 관련 질환 및 합병증 치료에 사용되는 강력한 비스포스포네이트 의약품에 초점을 맞추고 있습니다. 조메타, 리클라스트 등 다양한 상품명으로 판매되는 졸레드론산은 파골세포를 통한 골흡수를 억제하는 질소 함유 비스포스포네이트 역할을 하며, 골다공증, 파제트병, 각종 암에 따른 골 전이 등의 병태 관리에 필수적인 약물입니다. 이 약의 독특한 작용 기전은 광물화된 뼈 매트릭스에 결합하여 파네실피롤린산 합성효소를 억제하여 파골세포의 기능을 효과적으로 파괴하고 골밀도 유지를 촉진하는 것입니다. 전 세계 의료 시스템이 인구 고령화와 뼈 관련 질환의 증가에 대응하기 위해 노력하고 있는 가운데, 졸레드론산과 같은 효과적인 치료 중재에 대한 수요는 지속적으로 증가하고 있습니다. 이 시장에는 병원 투여용 정맥주사 제제, 다양한 치료 적응증에 특화된 제제 등 다양한 제제가 있습니다. 최근 약물전달 시스템의 발전과 함께 전통적인 뼈 질환 이외의 임상 적용이 확대되면서 졸레드론산은 전 세계 다양한 헬스케어 환경에서 큰 시장 잠재력을 가진 다재다능한 치료제로 자리매김하고 있습니다.
시장 역학
졸레드론산 세계 시장은 몇 가지 강력한 촉진요인에 의해 뒷받침되고 있습니다. 주요 촉진요인은 빠르게 고령화되고 있는 세계 인구, 골다공증, 골절 및 관련 합병증에 대한 감수성 증가로 인해 효과적인 골 강화 요법에 대한 수요가 크게 증가하고 있다는 점입니다. 특히, 골 전이가 많은 유방암, 전립선암, 폐암의 유병률 증가는 골격 관련 질환의 예방과 악성 종양으로 인한 고칼슘혈증 관리에 중요한 역할을 하는 졸레드론산이 시장 성장에 큰 영향을 미치고 있습니다. 또한, 뼈 건강 관리의 중요성에 대한 의료진과 환자의 인식이 높아지고 뼈 질환을 조기에 발견할 수 있는 진단 능력이 향상됨에 따라 치료 채택률이 증가하고 있습니다. 그러나 턱뼈 괴사, 심방세동, 신장 합병증과 같은 잠재적 부작용을 포함한 뚜렷한 억제요인에 직면하고 있으며, 이는 장기적인 치료 프로토콜에 대해 의사와 환자 모두 주저하게 만드는 요인입니다. 비스포스포네이트 제제 승인에 대한 엄격한 규제 요건은 전문적인 의료 환경을 필요로 하는 정맥 투여의 복잡성과 함께 시장 진입의 또 다른 장벽으로 작용하고 있습니다. 또한, 다른 비스포스포네이트, 데노수맙, 새로운 뼈 표적 치료제와 같은 대체 치료 옵션이 출시되면서 경쟁 압력이 증가하고 있습니다. 그럼에도 불구하고, 희귀 골질환 치료로의 적용 확대, 다른 항암제와의 병용요법 가능성, 환자의 순응도를 개선하고 투여의 복잡성을 줄일 수 있는 새로운 전달 메커니즘의 개발 등을 통해 큰 비즈니스 기회가 창출되고 있습니다. 신흥 시장의 의료 인프라 성장, 의료비 증가, 뼈 건강에 대한 인식 개선 캠페인은 전 세계 졸레드론산 제조업체 및 유통업체들에게 미개척 시장 잠재력을 보여주고 있습니다.
본 조사의 주요 특징
- 세계의 졸레드론산(Zoledronic Acid) 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 이 보고서는 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 졸레드론산 시장의 주요 기업을 프로파일링합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 졸레드론산 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 졸레드론산 시장을 분석할 때 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER의 분석
- 인수합병 시나리오
- 업계 동향
제4장 졸레드론산 세계 시장, 적응증별, 2020-2032년
- 골다공증 치료와 예방
- 폐경후 골다공증
- 종양학 관련 적응증
- 골전이
- 기타(뼈의 파제트병, 소아 골형성 부전증(허가외 사용) 등)
제5장 졸레드론산 세계 시장, 투여 경로별, 2020-2032년
- 정맥내 주입
- 경구 투여
제6장 졸레드론산 세계 시장, 용량별, 2020-2032년
- 4mg/100mL 일회용 보틀
- 4mg/5mL 일회용 바이알
- 100mL 주입 용액에 5mg을 첨가
제7장 세계의 졸레드론산 시장, 연령층별, 2025-2032년
- 노인
- 성인
제8장 졸레드론산 세계 시장, 성별, 2020-2032년
- 여성
- 남성
제9장 세계의 졸레드론산 시장, 제품 유형별, 2020-2032년
- 브랜드 졸레드론산
- 제네릭 졸레드론산
제10장 세계의 졸레드론산 시장, 최종사용자별, 2020-2032년
- 병원과 전문 클리닉
- 암 치료 센터
- 외래 수술 센터(ASC)
- 장기간병 시설
- 기타(조사기관 등)
제11장 세계의 졸레드론산 시장, 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Sanofi S.A.
- GSK(GlaxoSmithKline)
- Roche Holding AG
- Pfizer Inc.
- Bayer AG
- AbbVie Inc.
- Johnson & Johnson
- Astellas Pharma Inc.
- Ashfield Healthcare
- Hikma Pharmaceuticals plc
제13장 애널리스트의 추천사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고문헌과 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Zoledronic Acid Market is estimated to be valued at USD 5.38 Bn in 2025 and is expected to reach USD 7.62 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 5.38 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.10% | 2032 Value Projection: | USD 7.62 Bn |
The global zoledronic acid market represents a critical segment within the pharmaceutical industry, focusing on a potent bisphosphonate medication primarily utilized for treating bone-related disorders and complications. Zoledronic acid, marketed under various brand names including Zometa and Reclast, functions as a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption, making it essential for managing conditions such as osteoporosis, Paget's disease, and bone metastases associated with various cancers. The medication's unique mechanism of action involves binding to mineralized bone matrix and inhibiting farnesyl pyrophosphate synthase, effectively disrupting osteoclast function and promoting bone density preservation. As healthcare systems worldwide grapple with aging populations and increasing incidences of bone-related pathologies, the demand for effective therapeutic interventions like zoledronic acid continues to escalate. The market encompasses various formulations including intravenous solutions for hospital administration and specialized preparations for different therapeutic indications. Recent advancements in drug delivery systems, coupled with expanding clinical applications beyond traditional bone disorders, have positioned zoledronic acid as a versatile therapeutic agent with significant market potential across diverse healthcare settings globally.
Market Dynamics
The global zoledronic acid market is propelled by several compelling drivers, with the primary catalyst being the rapidly aging global population that inherently faces increased susceptibility to osteoporosis, bone fractures, and related complications, creating substantial demand for effective bone-strengthening therapies. The rising prevalence of cancer, particularly breast, prostate, and lung cancers that frequently metastasize to bones, significantly drives market growth as zoledronic acid serves as a crucial intervention for preventing skeletal-related events and managing hypercalcemia of malignancy. Additionally, growing awareness among healthcare professionals and patients about the importance of bone health management, coupled with improved diagnostic capabilities for early detection of bone disorders, contributes to increased treatment adoption rates. However, the market faces notable restraints including potential adverse effects such as osteonecrosis of the jaw, atrial fibrillation, and renal complications, which create hesitancy among both physicians and patients regarding long-term treatment protocols. Stringent regulatory requirements for bisphosphonate approvals, coupled with the complexity of intravenous administration requiring specialized healthcare settings, pose additional barriers to market accessibility. Furthermore, the availability of alternative treatment options including other bisphosphonates, denosumab, and emerging bone-targeting therapies intensifies competitive pressure. Nevertheless, significant opportunities emerge through expanding applications in treating rare bone diseases, potential combination therapies with other anticancer agents, and development of novel delivery mechanisms that could improve patient compliance and reduce administration complexity. The growing healthcare infrastructure in emerging markets, combined with increasing healthcare expenditure and awareness campaigns about bone health, presents substantial untapped market potential for zoledronic acid manufacturers and distributors worldwide.
Key Features of the Study
- This report provides in-depth analysis of the global zoledronic acid market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global zoledronic acid market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., GSK (GlaxoSmithKline), Roche Holding AG, Pfizer Inc., Bayer AG, AbbVie Inc., Johnson & Johnson, Astellas Pharma Inc., Ashfield Healthcare, and Hikma Pharmaceuticals plc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global zoledronic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global zoledronic acid market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Osteoporosis Treatment & Prevention
- Postmenopausal Osteoporosis
- Male Osteoporosis
- Glucocorticoid-Induced Osteoporosis
- Oncology-Related Indication
- Bone Metastases
- Breast
- Prostate
- Lung Cancer
- Multiple Myeloma
- Hypercalcemia of Malignancy (HCM)
- Others (Paget's Disease of Bone, Pediatric Osteogenesis Imperfecta [off-label use], etc.)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous infusion
- Oral administration
- Dosage Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 4 mg/100 mL single-use ready-to-use bottle
- 4 mg/5 mL single-use vial
- 5 mg in a 100 mL ready to infuse solution
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Geriatric
- Adult
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Female
- Male
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded Zoledronic Acid
- Generic Zoledronic Acid
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals & Specialty Clinics
- Cancer Treatment Centers
- Ambulatory Surgical Centers (ASCs)
- Long-term care facilities
- Others (Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Sanofi S.A.
- GSK (GlaxoSmithKline)
- Roche Holding AG
- Pfizer Inc.
- Bayer AG
- AbbVie Inc.
- Johnson & Johnson
- Astellas Pharma Inc.
- Ashfield Healthcare
- Hikma Pharmaceuticals plc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Zoledronic Acid Market, By Indication
- Global Zoledronic Acid Market, By Route of Administration
- Global Zoledronic Acid Market, By Dosage Strength
- Global Zoledronic Acid Market, By Age Group
- Global Zoledronic Acid Market, By Gender
- Global Zoledronic Acid Market, By Product Type
- Global Zoledronic Acid Market, By End User
- Global Zoledronic Acid Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Zoledronic Acid Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Osteoporosis Treatment & Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Postmenopausal Osteoporosis
- Male Osteoporosis
- Glucocorticoid-Induced Osteoporosis
- Oncology-Related Indication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bone Metastases
- Breast
- Prostate
- Lung Cancer
- Multiple Myeloma
- Hypercalcemia of Malignancy (HCM)
- Others (Paget's Disease of Bone, Pediatric Osteogenesis Imperfecta [off-label use], etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Zoledronic Acid Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intravenous infusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral administration
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Zoledronic Acid Market, By Dosage Strength, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 4 mg/100 mL single-use ready-to-use bottle
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 4 mg/5 mL single-use vial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- 5 mg in a 100 mL ready to infuse solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Zoledronic Acid Market, By Age Group, 2025-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Zoledronic Acid Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Zoledronic Acid Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded Zoledronic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic Zoledronic Acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Zoledronic Acid Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals & Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term care facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Zoledronic Acid Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ashfield Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
